Eupraxia Pharmaceuticals Inc.

TSX:EPRX.TO

3.47 (CAD) • At close October 17, 2024
Bedrijfsnaam Eupraxia Pharmaceuticals Inc.
Symbool EPRX.TO
Munteenheid CAD
Prijs 3.47
Beurswaarde 123,610,422
Dividendpercentage 0%
52-weken bereik 3.1 - 7.64
Industrie Biotechnology
Sector Healthcare
CEO Dr. James A. Helliwell FRCPC, M.D.
Website https://www.eupraxiapharma.com

An error occurred while fetching data.

Over Eupraxia Pharmaceuticals Inc.

Eupraxia Pharmaceuticals Inc., a clinical stage biotechnology company, engages in the discovery, development, and marketing of technologies in the biotechnology sector. The company's lead product candidate is EP-104IAR, which is in a Phase II clinical trial for the treatment of unmet medical needs and for pain relief for knee osteoarthritis,

Vergelijkbare Aandelen

Helix BioPharma Corp. logo

Helix BioPharma Corp.

HBP.TO

1.23 CAD

Antibe Therapeutics Inc. logo

Antibe Therapeutics Inc.

ATE.TO

0.295 CAD

Financiële Gegevens

Cijfers zijn in miljoenen (CAD)

Cijfers zijn in miljoenen (CAD)